Cookie Einstellungen

Zur Optimierung der Benutzerfreundlichkeit setzen wir Cookies ein. Wählen Sie aus, welche Cookies diese Webseite verwenden darf.  Datenschutzerklärung

Nur technisch erforderliche Cookies, die für die grundlegenden Funktionen unserer Webseite nötig sind, werden gesetzt.


COAT – an exceptionally efficient tumor vaccination approach

Reference Number TO 15-00358


The exploration of new strategies against tumors is a major challenge of current research. In this respect, several studies could verify the general effectiveness of immunotherapeutic approaches. Based on these promising research results, immunotherapy is considered to be a key for directed and efficient eradication of tumors. However, although enormous efforts have been spent on the development of new vaccination protocols, none of the novel strategies could reveal a sufficient efficacy against cancer. Thus, there is still a strong need for the development of new and efficient immunotherapeutic strategies to fight cancer.

COAT – an exceptionally efficient tumor vaccination approach

COAT significantly increases the specific CD8+ T-cell response compared to other vaccination protocols


The newly developed technology comprises an impressively effective and antigen-specific vaccination protocol, referred to as COAT. The separate administration of two well-defined compositions in a prime-boost vaccination approach elicits a very efficient and specific T-cell response within comparatively short time. Although the novel strategy is preferably directed against tumor cells, the identified combination of compounds may also be used to raise T-cell immunity against intracellular bacterial or viral infections. Thus, the new technology gives rise to an excellent multifunctional tool for the immunotherapeutic treatment of diverse clinical indications with a particular focus on cancer.

Commercial Opportunity

In-licensing or collaboration for further development is possible.

Development Status

In vivo studies in mice were performed to validate proof of principle.

Patent Situation

Patent applications have been filed in Europe and US with priority of 2014.

Further Reading

Nimanong S, Ostroumov D, Wingerath J, Wirth TC et al. 2017. CD40 Signaling Drives Potent Cellular Immune Responses in Heterologous Cancer Vaccinations. Cancer Res. 77(8): 1918-1926.
Brinkhoff B, Ostroumov D, Heemcke J, Woller N et al. 2014. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers. Eur J Immunol. 44:1213-1224.